Dr. Heidi Overton, President Trump’s nominee to lead the Food and Drug Administration (FDA), appeared before the Senate committee on Thursday for her confirmation hearing, offering limited clarity on whether she would challenge Trump’s influence over agency policies. During the hearing, Dr. Overton pledged to affirm the safety and efficacy of currently approved vaccines but declined to commit to resisting presidential interference on issues such as tobacco regulation or misinformation regarding vaccines and over-the-counter medications like Tylenol.
Senator Bill Cassidy, a Republican physician from Louisiana and chair of the committee overseeing the nomination, underscored the importance of independent scientific leadership at the FDA. Citing former Health Secretary Robert F. Kennedy Jr.’s broken promise to maintain vaccine access due to presidential direction, Cassidy pressed Dr. Overton to confirm she would uphold sound science regardless of political pressure. Dr. Overton responded by emphasizing her “robust” discussions with President Trump and defended his decision-making as being in the nation’s best interests, stopping short of indicating whether she would oppose presidential directives.
Dr. Overton, who has a background as a White House domestic policy adviser and ties to conservative think tanks, has publicly criticized the abortion medication mifepristone in the past. At the hearing, she acknowledged the drug’s current FDA-approved safety and effectiveness but refrained from committing to any specific conclusions from an impending FDA safety review requested by some Republican lawmakers. Senator Josh Hawley, a prominent opponent of abortion, expressed concern over her noncommittal stance.
The nominee also faced questions regarding alleged political interference in the FDA’s tobacco policies. Senators referenced reports that following a $5 million donation from Reynolds American to a pro-Trump political action committee and a subsequent meeting with the president at his golf club, FDA officials authorized flavored e-cigarettes, a reversal that contributed to the resignation of then-FDA commissioner Dr. Marty Makary. Dr. Overton rejected the implication that these actions were directly influenced by campaign contributions or meetings, reiterating her belief in the president’s commitment to public health. She indicated openness to revisiting e-cigarette regulatory standards in collaboration with lawmakers.
Dr. Overton defended vaccines broadly, endorsing the measles, mumps, and rubella (MMR) vaccine amid concerns raised by Trump and remarks during an August event questioning vaccine safety. In contrast to some of Trump’s statements, she affirmed the vaccine as a critical public health tool.
If confirmed, Dr. Overton would oversee numerous significant FDA policy areas, including the regulation of medications, food safety, medical devices, and emerging technologies like artificial intelligence (AI) applications in healthcare. The agency is currently evaluating frameworks for regulating advanced AI tools capable of performing clinical tasks such as prescribing medications. Several pilots involving AI, including chatbots providing therapy for Medicare patients, are proceeding under relaxed oversight due to the absence of established rules.
Food safety remains a priority following a cyclospora outbreak linked to lettuce processed at a facility in Mexico. The FDA is investigating and developing responses to such incidents. Additionally, the agency has proposed a new rule to tighten oversight of new food chemicals introduced by manufacturers, though critics say the rule’s exemptions undermine its effectiveness. Dr. Overton acknowledged the need for increased resources within the agency’s human foods program to enforce new regulations adequately.
No date has been set for the committee vote on her nomination, which comes as the FDA prepares to revisit other contentious issues, including the authorization of untested peptide injections and ongoing debates over vaccine recommendations for common childhood illnesses such as flu and respiratory syncytial virus.